What people are saying - Write a review
We haven't found any reviews in the usual places.
Pathophysiology and etiology
Current therapeutic options
4 other sections not shown
Other editions - View all
abatacept active rheumatoid arthritis adalimumab agents anakinra Ann Rheum anti-TNFo antigen Arthritis Rheum associated autoimmune chronic citrullinated Clin clinical trials College of Rheumatology combination therapy compared controlled trial corticosteroids cyclosporin cytokines decrease development of RA disease activity disease-modifying antirheumatic drugs DMARD dose double-blind early rheumatoid arthritis effects efficacy Engl etanercept function genes genetic groups human hydroxychloroquine immune responses Immunol improvement incidence infections inflammation inflammatory infliximab inhibition interleukin joint damage leflunomide low-dose lymphocytes macrophages methotrexate mg/day mg/kg molecule monoclonal antibody monotherapy mortality NSAIDs oral patients receiving patients with active patients with rheumatoid Phase placebo placebo-controlled trial potential proinflammatory protein RA patients radiographic progression randomized receptor rheumatoid arthritis rheumatoid arthritis patients Rheumatol Rheumatology risk factor rituximab role safety sulfasalazine symptoms synovial fluid synoviocytes synovium T-cell T-cell activation target therapeutic tissue TNFo inhibitors tocilizumab toxicity treatment of RA treatment of rheumatoid tumor necrosis factor weeks